Impact of CYP3A4 Genotype on Voriconazole Exposure
- 29 August 2017
- journal article
- letter
- Published by Wiley in Clinical Pharmacology & Therapeutics
- Vol. 103 (2) , 185-186
Abstract
No abstract availableThis publication has 4 references indexed in Scilit:
- Pharmacogenetics of Voriconazole: CYP2C19 but Also CYP3A4 Need to Be GenotypedClinical Pharmacology & Therapeutics, 2017
- Response to “Pharmacogenetics of Voriconazole: CYP2C19 but Also CYP3A4 Need to Be Genotyped” - The Role of CYP3A4 and CYP3A5 Polymorphisms in Clinical Pharmacokinetics of VoriconazoleClinical Pharmacology & Therapeutics, 2017
- Impact of CYP2C19 genetic polymorphisms on voriconazole dosing and exposure in adult patients with invasive fungal infectionsInternational Journal of Antimicrobial Agents, 2016
- Effects of CYP3A4 polymorphisms on the plasma concentration of voriconazoleEuropean Journal of Clinical Microbiology & Infectious Diseases, 2014